SCHEMBL19808917

SCHEMBL19808917

COC(=O)c1ccc(Oc2ccc(Br)cc2)nc1C(C)Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.38
▸ EGLN1 Q9GZT9 1/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MAPT P10636 4/20 0.37
▸ AKR1C3 P42330 1/20 0.37
▸ AKR1C2 P52895 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ LMNA P02545 4/20 0.36
▸ RAB9A P51151 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ TDP1 Q9NUW8 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ P2RX3 P56373 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19808905 0.91 CYP1A2 (0.42) EGLN1SMN1; SMN2MAPTKDM4EALDH1A1
SCHEMBL19808864 0.89 P2RX3 (0.43) L3MBTL1SLC6A3EGLN1SMN1; SMN2MAPT
SCHEMBL19808892 0.89 HPGD (0.44) L3MBTL1SLC6A3EGLN1SMN1; SMN2KDM4E
SCHEMBL19808921 0.88 TDP1 (0.46) L3MBTL1SMN1; SMN2MAPTKDM4EALDH1A1
SCHEMBL19808858 0.86 LMNA (0.41) EGLN1SMN1; SMN2MAPTAKR1C3AKR1C2
SCHEMBL19808803 0.85 JAK2 (0.44) EGLN1MAPTKDM4ELMNARAB9A
SCHEMBL19808833 0.85 LMNA (0.51) EGLN1MAPTKDM4ELMNAGAA
SCHEMBL31554238 0.82 POLB (0.45) L3MBTL1SMN1; SMN2MAPTKDM4EALDH1A1
SCHEMBL19808901 0.80 P2RX3 (0.48) L3MBTL1SLC6A3EGLN1SMN1; SMN2MAPT
SCHEMBL19808816 0.80 L3MBTL1 (0.48) L3MBTL1EGLN1SMN1; SMN2MAPTAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3275881-B1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) 2021-08-04 — — EP disclosed
US-10100051-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) 2018-10-16 — — US disclosed
US-20180118739-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) 2018-05-03 — — US disclosed
EP-3275881-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) 2018-01-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118739-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF HIF1AN, EGLN3, EGLN2 L3MBTL1 4819/4885SLC6A3 3657/4885EGLN1 7/4885
US-10100051-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof HIF1AN, EGLN3, EGLN2 L3MBTL1 4819/4885SLC6A3 3657/4885EGLN1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback